NCT01212276 - A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

June 30, 2012

Study Completion Date

September 30, 2012

Conditions

Metastatic MelanomaMalignant Metastatic MelanomaAdvanced MelanomaMelanoma

Interventions

DRUG

MORAb-028

Cohort 1: 0.1 mg/kg IV on study day 1 only Cohort 2: 0.2 mg/kg IV on study day 1 only Cohort 3: 0.5 mg/kg IV on study day 1 only Cohort 4: 1.0 mg/kg IV on study day 1 only

Trial Locations (1)

10022

Memorial Sloan-Kettering Cancer Center, New York